Oncorus (ONCR) Stock Price

Oncorus Price

NASDAQ·CLOSED
0
​
Market closed

Oncorus stock price

Access this data via the Eulerpool API

Oncorus business model & stock analysis

Oncorus, Inc. engages in the research and development of a viral immunotherapy platform. The company is headquartered in Andover, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2020-10-02. The Company’s two product candidates from its self-amplifying RNA platform are ONCR-021 and ONCR-788. ONCR-021, a lead product candidate that is an IV administered viral RNA encoding an optimized genome of Coxsackievirus 21A (CVA21), is encapsulated within a lipid nanoparticle (LNP). The firm intends to develop ONCR-021 for non-small cell lung cancer, renal cell carcinoma, melanoma, anaplastic thyroid cancer, and hepatocellular carcinoma. The firm is also developing ONCR-788, which encodes for a modified version of the Seneca Valley Virus (SVV). The firm designed its HSV platform, including product candidate ONCR-719, to overcome the limitations in potency and in the ability to stimulate anti-tumor immunity that have both been encountered by previous viral immunotherapies and other immuno-oncology therapies.

Frequently asked questions about Oncorus

7 analysts currently rate the Oncorus stock: 0 recommend buying, 4 holding and 3 selling.

The Oncorus share (ONCR) is listed on 1 stock exchanges, including: NASDAQ (ONCR).

The revenue cannot currently be calculated for Oncorus.

The profit cannot currently be calculated for Oncorus.

The P/E ratio cannot be calculated for Oncorus at the moment.

The P/S cannot be calculated for Oncorus currently.

The Eulerpool Quality Score for Oncorus is 2/10.

The ISIN of Oncorus is US68236R1032. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Oncorus is ONCR. The ticker symbol is used to trade Oncorus shares on the stock exchange.

Fair ValueTerminal
148.30 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Oct 2, 2020
ISIN
US68236R1032
Cusip
68236R103
Market capitalization
3.29 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2023
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.05
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-96.90 %
Last updated Oct 10, 2026, 12:27 AM

Oncorus Peer Group

Oncorus Ticker

NASDAQ · ONCR

Oncorus FIGI

ONCR:US · BBG00DDYJ7N1ONCR:PQ · BBG00X9DZTF1ONCR:UV · BBG00X9DZTG0ONCRUSD:XH · BBG011MCFF41ONCRUSD:XF · BBG011MCFF69ONCRUSD:XE · BBG011MCFF87ONCRUSD:XL · BBG011MCFFB3ONCRUSD:XG · BBG011MCFFC2ONCRUSD:XO · BBG011MCFFD1ONCRUSD:XA · BBG011MCFFJ5ONCRUSD:XT · BBG011MCFFL2ONCRUSD:XW · BBG011MCFFM1

All fundamentals and in-depth analysis of Oncorus

Our stock analysis for Oncorus stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncorus. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.